Literature DB >> 26694609

The Triggering Receptor Expressed on Myeloid Cells 2: A Molecular Link of Neuroinflammation and Neurodegenerative Diseases.

Jochen Walter1.   

Abstract

The triggering receptor expressed on myeloid cells (TREM) 2 is a member of the immunoglobulin superfamily of receptors and mediates signaling in immune cells via engagement of its co-receptor DNAX-activating protein of 12 kDa (DAP12). Homozygous mutations in TREM2 or DAP12 cause Nasu-Hakola disease, which is characterized by bone abnormalities and dementia. Recently, a variant of TREM2 has also been associated with an increased risk for Alzheimer disease. The selective expression of TREM2 on immune cells and its association with different forms of dementia indicate a contribution of this receptor in common pathways of neurodegeneration.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Alzheimer disease; cell signaling; microglia; neurodegenerative disease; neuroinflammation; protein processing

Mesh:

Substances:

Year:  2015        PMID: 26694609      PMCID: PMC4813462          DOI: 10.1074/jbc.R115.704981

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  93 in total

Review 1.  DAP12 signaling: from immune cells to bone modeling and brain myelination.

Authors:  Marco Colonna
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 2.  Immune attack: the role of inflammation in Alzheimer disease.

Authors:  Frank L Heppner; Richard M Ransohoff; Burkhard Becher
Journal:  Nat Rev Neurosci       Date:  2015-06       Impact factor: 34.870

3.  The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-β (Aβ) aggregation.

Authors:  Iryna Benilova; Rodrigo Gallardo; Andreea-Alexandra Ungureanu; Virginia Castillo Cano; An Snellinx; Meine Ramakers; Carmen Bartic; Frederic Rousseau; Joost Schymkowitz; Bart De Strooper
Journal:  J Biol Chem       Date:  2014-09-24       Impact factor: 5.157

4.  The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E.

Authors:  Charles C Bailey; Lindsey B DeVaux; Michael Farzan
Journal:  J Biol Chem       Date:  2015-09-15       Impact factor: 5.157

Review 5.  Frontotemporal dementia: implications for understanding Alzheimer disease.

Authors:  Michel Goedert; Bernardino Ghetti; Maria Grazia Spillantini
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

Review 6.  Structure, expression pattern and biological activity of molecular complex TREM-2/DAP12.

Authors:  Agnieszka Paradowska-Gorycka; Monika Jurkowska
Journal:  Hum Immunol       Date:  2013-02-28       Impact factor: 2.850

Review 7.  Neuropathological spectrum of frontal lobe dementias.

Authors:  Enikö Kövari
Journal:  Front Neurol Neurosci       Date:  2009-01-26

8.  Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation.

Authors:  Laura Piccio; Cecilia Buonsanti; Marina Cella; Ilaria Tassi; Robert E Schmidt; Chiara Fenoglio; John Rinker; Robert T Naismith; Paola Panina-Bordignon; Nadia Passini; Daniela Galimberti; Elio Scarpini; Marco Colonna; Anne H Cross
Journal:  Brain       Date:  2008-09-12       Impact factor: 13.501

9.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

Review 10.  Neuroinflammation in Alzheimer's disease.

Authors:  Michael T Heneka; Monica J Carson; Joseph El Khoury; Gary E Landreth; Frederic Brosseron; Douglas L Feinstein; Andreas H Jacobs; Tony Wyss-Coray; Javier Vitorica; Richard M Ransohoff; Karl Herrup; Sally A Frautschy; Bente Finsen; Guy C Brown; Alexei Verkhratsky; Koji Yamanaka; Jari Koistinaho; Eicke Latz; Annett Halle; Gabor C Petzold; Terrence Town; Dave Morgan; Mari L Shinohara; V Hugh Perry; Clive Holmes; Nicolas G Bazan; David J Brooks; Stéphane Hunot; Bertrand Joseph; Nikolaus Deigendesch; Olga Garaschuk; Erik Boddeke; Charles A Dinarello; John C Breitner; Greg M Cole; Douglas T Golenbock; Markus P Kummer
Journal:  Lancet Neurol       Date:  2015-04       Impact factor: 44.182

View more
  24 in total

1.  Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease.

Authors:  L M Bekris; M Khrestian; E Dyne; Y Shao; J A Pillai; S M Rao; S M Bemiller; B Lamb; H H Fernandez; J B Leverenz
Journal:  J Neuroimmunol       Date:  2018-03-20       Impact factor: 3.478

2.  Targeted sequencing approach to identify genetic mutations in Nasu-Hakola disease.

Authors:  Jun-Ichi Satoh; Motoaki Yanaizu; Youhei Tosaki; Kenji Sakai; Yoshihiro Kino
Journal:  Intractable Rare Dis Res       Date:  2016-11

3.  Triggering receptor expressed on myeloid cells-2 expression in the brain is required for maximal phagocytic activity and improved neurological outcomes following experimental stroke.

Authors:  Kota Kurisu; Zhen Zheng; Jong Youl Kim; Jian Shi; Atsushi Kanoke; Jialing Liu; Christine L Hsieh; Midori A Yenari
Journal:  J Cereb Blood Flow Metab       Date:  2018-12-07       Impact factor: 6.200

4.  Opposing Functions of Microglial and Macrophagic TNFR2 in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.

Authors:  Han Gao; Matt C Danzi; Claire S Choi; Mehran Taherian; Camilla Dalby-Hansen; Ditte G Ellman; Pernille M Madsen; John L Bixby; Vance P Lemmon; Kate L Lambertsen; Roberta Brambilla
Journal:  Cell Rep       Date:  2017-01-03       Impact factor: 9.423

5.  Heterozygote galactocerebrosidase (GALC) mutants have reduced remyelination and impaired myelin debris clearance following demyelinating injury.

Authors:  Nicole J Scott-Hewitt; Christopher J Folts; Jessica M Hogestyn; Gavin Piester; Margot Mayer-Pröschel; Mark D Noble
Journal:  Hum Mol Genet       Date:  2017-08-01       Impact factor: 6.150

6.  TREM2 promotes natural killer cell development in CD3-CD122+NK1.1+ pNK cells.

Authors:  Hwa-Youn Lee; Eun-Hee Lee; Jawoon Yi; Kon-Young Ji; Su-Man Kim; Ha-Rim Choi; Su-Min Yee; Hyung-Sik Kang; Eun-Mi Kim
Journal:  BMC Immunol       Date:  2021-05-12       Impact factor: 3.615

7.  In vivo evidence for the contribution of peripheral circulating inflammatory exosomes to neuroinflammation.

Authors:  Jing Jing Li; Bin Wang; Mahesh Chandra Kodali; Chao Chen; Eunhee Kim; Benjamin John Patters; Lubin Lan; Santosh Kumar; Xinjun Wang; Junming Yue; Francesca-Fang Liao
Journal:  J Neuroinflammation       Date:  2018-01-08       Impact factor: 8.322

8.  Triggering Receptor Expressed on Myeloid Cells 2 Overexpression Inhibits Proinflammatory Cytokines in Lipopolysaccharide-Stimulated Microglia.

Authors:  Xiaobao Zhang; Fang Yan; Jizheng Cui; Yong Wu; Hengfei Luan; Miaomiao Yin; Zhibin Zhao; Jiying Feng; Jinwei Zhang
Journal:  Mediators Inflamm       Date:  2017-10-18       Impact factor: 4.711

9.  Key Aging-Associated Alterations in Primary Microglia Response to Beta-Amyloid Stimulation.

Authors:  Cláudia Caldeira; Carolina Cunha; Ana R Vaz; Ana S Falcão; Andreia Barateiro; Elsa Seixas; Adelaide Fernandes; Dora Brites
Journal:  Front Aging Neurosci       Date:  2017-08-31       Impact factor: 5.750

10.  Reduced Serum sRANKL and sTREM2 Levels in High-Grade Gliomas: Association with Prognosis.

Authors:  Mustafa Efendioğlu; Elif Şanli; Ceren Türkoğlu; Naci Balak
Journal:  Noro Psikiyatr Ars       Date:  2021-06-03       Impact factor: 1.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.